In addition to genes with significant alterations and indels, including TP53 (Q < 2.2 × 1016), CDH1 (Q < 2.2 × 1016), and ARID1A (Q = 8.7 × 108; 29 of 186 samples [15.6%] with alterations) (eFigure 4 in Supplement 1), which were previously identified in a TCGA cohort of patients with stomach adenocarcinoma (STAD) (11% frequency),12 the MutSigCV algorithm identified several SMG genes, including HRCT1, KRTAP5-4, RAB21, PIGR, FAM136A, TGFBR2, BAP1, and ELF3, based on our data set (Figure 4A; eTable 1 in Supplement 2). This evidence concerns the gene TGFBR2 and gastric adenocarcinoma.